Antares Pharma: Acquisition by HalozymeI am a little sad to see Antares sell out to Halozyme. I thought that the rubber was just starting… Antares: The Future Looks Really, Really Bright (ATRS, Buy, $4.18)Investment Thinking The fourth quarter conference call was very encouraging to me. The investment thesis is coming together much better and… Antares: Encouraging Revenue Guidance (ATRS, Buy, $4.00)Key Point I think that the stock has the potential to double in 2021. New Revenue Guidance Antares has just issued guidance… Antares: Xyosted Sales Projections for 2020 Through 2023 (ATRS, Buy, $2.62)Sales Projections for Xyosted Xyosted just completed its sixth full quarter of sales since its launch in 4Q, 2018. Almost all… Why Bother with Antares? (ATRS, Buy, $2.86)Investment Perspective Periodically, I get a comment from one subscriber regarding Antares to the effect of why are you bothering… Antares (ATRS, Buy, $2.72) Effect of Covid-19 Appears Modest So Far On Company and Xyosted in ParticularInvestment Overview Antares stock has been more impacted by the market sell off than many other biotechnology stocks which have rebounded… Antares: Detailed Sales and Earnings Projections for 2020, 2021 and 2022 (ATRS, Buy, $4.86)Objective of This Report Antares is an extremely difficult company to model on a sales and earnings basis. Its core technology… Antares Pharma: Highlights from Presentation at Jefferies Healthcare Conference: (ATRS, Buy, $4.79)Purpose of Report I just listened to the presentation by Antares at the Jefferies conference in London on Wednesday, November 20… Antares Pharmaceuticals: Projecting Very Strong Growth in Xyosted Sales for 2020, 2021 and 2022 (ATRS, Buy, $3.89)Key Points In my sales and earnings model for 2020, I will be using a working estimate of $53.6 million… Antares Pharma: Quick Take on Implication of 3Q Results for Future Growth (ATRS, Buy, $3.70)Key Points: Xyosted launch continues to impress. Projecting sales of $22 million in 2019 and over $50 million in 2019 AMAG Pharmaceuticals: AdCom Votes 9 to 7 to Remove Makena from the Market, but I Don’t Think It Will Happen: AMAG (AMAG, $9.80), Antares Pharma (ATRS, $3.40, Buy)The FDA AdCom meeting voted 9 to 7 to withdraw Makena from the market. However, 6 of 7 practicing OB/GYNs… AMAG Pharmaceuticals (AMAG, $12.20); Antares (ATRS, Buy, $3.59) What Will FDA AdCom Recommend on Makena in the Aftermath of Failed Prolong Trial?Key Conclusions I believe that there is a 95% probability that Makena will remain on the market and only a 5%… Antares: Impressive Xyosted Prescription Trends Continue (ATRS, Buy, $3.30)Key Points: Xyosted prescription trends remain impressive and based on audit data for the last 11 weeks, there has been… Antares: Update on Sales Projections for Xyosted (ATRS, $3.30, Buy)Investment Thesis I have seen seven plus months of data on prescription trends for Xyosted as estimated by the prescription auditing… Antares: Highlights from 2Q, 2019 Conference Call (ATRS, $3.29, Buy)Introduction I have heard encouraging comments on my recently announced approach of doing shorter, less pedantic reports on new companies. This… Antares Pharma: The Xyosted Launch Continues to Look Good (ATRS, Buy, $3.37)Investment Thesis The cornerstone of my positive investment thesis for Antares is Xyosted, which was fully launched in January 2019. While… Antares Pharma: Detailed Sales and Earnings Model Through 2021 (ATRS, $2.85, Buy)Investment Thesis Recently, I have received a couple of sarcastic comments to the effect that this stock has gone nowhere for… Antares Pharma: The Xyosted Launch Looks Like it will Meet or Beat Wall Street Expectations for 2019 (ATRS, Buy, $2.90)Investment Thesis The cornerstone of my positive investment thesis for Antares is Xyosted, which was fully launched in January 2019. While… Antares: Tracking Report on Xyosted Prescriptions (ATRS, Buy, $2.88)Introduction and Overview I have obtained access to weekly prescription trends for Xyosted which I will publish periodically. Marketing began on… Antares (ATRS, Buy, $3.51); AMAG Pharmaceuticals (AMAG, $11.73) First Thoughts about How the PROLONG Study Could Affect Makena UsageIntroduction On Friday, the PROLONG clinical study was released that showed no difference in outcomes between Makena and placebo. This was… Antares: Sales Growth Guidance for 2019 is Extremely Bullish (ATRS, $3.60, Buy)
Antares just reported Antares: Multiple New Product Launches Make for Extreme Complexity in Earnings Forecasts for 2019 to 2021 (ATRS, Buy, $3.59)Investment Thesis in Brief: In this report, I have put together an earnings forecast projecting EPS of (0.04) in 2019, $0.19… Antares: Xyosted is Approved; Let the Good Times Roll (ATRS, Buy, $3.77)Investment Thesis At Last, Three Major Product Approvals in 2018 It has been a torturous wait for Antares’ very promising pipeline to… Antares: Investment Story has Shifted from Pipeline Promise to Commercial Potential (ATRS, $3.74, Buy)Investment Summary At long last, the exciting new product potential of Antares is becoming a commercial reality. A very significant milestone… Antares: Recent Launch of Makena Subcu Auto Injector and Probable Launches of Xyosted and AB Rated Generic to EpiPen Could Make for an Outstanding Price Performance in 2018 (ATRS, Buy, $2.36)Key Investment Issues In this report I focus on three very important product related issues that will likely drive the… Antares Pharma: Approval of Xyosted on or before September 29, 2018 Is Highly Probable (ATRS, Buy, $2.12)Background on Xyosted NDA Resubmission Following Complete Response Letter The original PDUFA date for the Xyosted NDA was October 20, 2017,… Antares: FDA Comments from Type A Meeting Are a Best Case Outcome for Xyosted (ATRS, $2.13, Buy)Management Comments on Type A Meeting Antares released the following comment on March 27, 2018 that deals with the Complete Response… Antares: Things Are Looking Up (ATRS, Buy, $2.22)Overview of Report I listened to the presentation by CEO Bob Apple at the Raymond James conference on March 5th and… Antares Pharma: Makena SC Approval is a Big Positve; There are more Approvals to Come (ATRS, Buy, $2.35)Investment Thesis Finally, the FDA comes through with the approval for Makena SC. My Buy recommendation on Antares is based on… Antares Pharma: Update on Xyosted (ATRS, Buy, $2.34)Regulatory Update Antares announced that it has scheduled a Type A meeting with FDA for Xyosted which is intended to resolve… Antares' Response to Complete Response Letter on Xyosted is in Line with My Expectations (ATRS, Buy, $2.05)Antares Pharma announced on December 21st that it had submitted a request to the FDA for a type A meeting… Antares Pharma: My Hypothesis on Issues that Resulted in the CRL for Xyosted and Potential Timing of Approval (ATRS. Buy, $1.63)Investment Thesis Xyosted is viewed by investors as the most important product in Antares” broad pipeline. In anticipation of approval… Antares: Approval of Xyosted is a Matter of When, Not If (ATRS, $2.12, Buy)The Issue Antares received a complete response letter for Xyosted that did not cite any questions relating to efficacy, manufacturing, quality… Antares Pharma: FDA Action to not Approve Xyosted on its October 20, 2017 PDUFA Date is Perplexing (ATRS, Buy, $2.23)Overview Investors have had high confidence that Xyosted would be approved by the FDA on its October 20, 2017 PDUFA date.… Antares Pharma: This Small, Emerging Biotechnology Company Is Poised for Explosive Growth Based on Five Major New Product Introductions by 2020 (ATRS, Buy, $3.02Investment Thesis Antares is one of my top recommendations based on its extremely impressive pipeline prospects. In a March 23, 2017… Antares: AMAG Submits Supplemental New Drug Application to FDA for Makena® Auto-Injector for Subcutaneous Use: (Antares (ATRS, Buy, $2.86)AMAG announced on April17, 2017 that it had submitted a sNDA for the Makena Auto-Injector. This was in line with… Antares: Pipeline is Bursting with Late Stage Products (ATRS, $2.77, Buy)Key Points: Antares has an impressive portfolio of seven new products that could lead to explosive growth over the next… AMAG Pharmaceuticals: Will FDA Approve Makena SC (AMAG, Neutral, $21.75)Importance of Makena SC to AMAG? AMAG is engaged in a high stakes clinical development program in which it is endeavoring… AMAG and Antares: Update on the Development of Makena SC (AMAG, Neutral, $24.40) (ATRS, Buy, $2.04)Key Points: Recent announcement that AMAG will not pursue Orphan Drug Exclusivity for Makena SC has hammered the stock of… SmithOnStocks Top Stock Picks for 2017, January 3, 2017Purpose of this Report I last summarized my stock recommendations in a September 12, 2016 report. There has been little change… Antares: Teva Projects Launch of AB Rated Generic to EpiPen in Early 2018 (ATRS, Buy, $1.87)Eyal Desheh is the Chief Financial Officer of Teva. During the recent third quarter conference call, he answered a question… Antares: Some Key Points from 3Q, 2016 Conference Call (ATRS, Buy, $1.84)Investment Opinion In my opinion, Antares is substantially undervalued. My price target is $6 60 in 2018. The thinking behind this… Antares: Updates on QST and AB Generic to EpiPen; Reiteration of Buy Recommendation (ATRS, Buy, $1.65)Overview and Investment Opinion In my opinion, Antares is substantially undervalued. My price target is $6 60 $8 in 2018 and… Antares; Are Mylan's Woes A Potential Positive for AB Rated Generic to EpiPen (ATRS, $1.37, Buy)You cannot turn on the business news channels without hearing extensive comments and condemnation by pundits and politicians about Mylan's aggressive… Antares: Comment on Strength in the Stock Price (ATRS, $1.29, Buy)A number of people have asked me if I know of any specific reason for the strength in Antares's stock… Antares Pharmaceuticals: Teva Launches AB Generic to Imitrex (ATRS, Buy, $1.06)Teva announced today the launch of its AB rated generic to Imitex (sumatriptan). Remember that Antares books revenues from Teva… Antares Pharmaceuticals: Highlights on Makena from AMAG Pharmaceuticals Analyst Day (ATRS, $1.14, Buy)Report Overview Antares and AMAG Pharmaceuticals are jointly developing a new subcutaneous formulation of AMAG’s key drug Makena which is currently… Antares: Presentation Highlights from Deutsche Bank Conference (ATRS, Buy, $0.97)Overview I listened to CEO Bob Apple speak at the Deutsche Bank conference and wanted to pass along a few pieces… Antares: AMAG Issues Guidance on Timing of Subcutaneous Makena (ATRS, Buy, $1/05)I recently wrote a report on Antares entitled Makena has the Potential to Make a Very Significant Contribution to EPS that… Antares: An Outstanding Product Pipeline Promises Dramatic Growth Through 2022 (ATRS, Buy, $0.92)Investment Thesis in Brief If you like numbers, you will like this report. It is a very detailed analysis of the… Antares: Makena Has the Potential to Make a Very Significant Contribution to EPS (ATRS, $0.85. Buy)Investment Thesis The launch of Otrexup has been extremely disappointing in contrast to my high expectations. Medac launched a competitive… Antares: Disappointing News on AB Rated Version of EpiPen (ATRS, $0.95)Investment Perspective Teva filed a 6-K regulatory document last night that stated: “Teva received a complete response letter on February 23, 2016 relating… Antares: Undeterred by the Poor Stock Performance I Continue to Pound the Table (ATRS. Buy, $1.30)Upcoming Catalysts This is a detailed note updating my thinking on Antares and discussing how I come up with my 2017… Antares: An Update on My Investment Thinking (ATRS, Buy, $1.33)Investment Thesis This has been a very disappointing year for Antares investors; the stock closed at $2.57 on December 31, 2014… Antares: The Stock Price Does Not Reflect the Fundamentals (ATRS, $1.60, Buy)Introduction Antares recently updated its corporate presentation on their website. .There were several slides in the presentation that reinforce my confidence… Quick Take on Antares Following 2Q, 2015 Conference Call (ATRS, Buy, $2.10)Investment Opinion Antares stock has been pummeled by the “so far” disappointing launch of Otrexup and uncertainty as to when or… Antares: One of My Top Stock Picks for 2015 and 2016 (ATRS, Buy, $2.40, For Paid Subscribers)Introduction to Report One of my assets is also one of my biggest drawbacks. When I am writing on a Company… Comments on Antares, Kite Pharma and Northwest BiotherapeuticsSmithOnStocks Mailbox My mailbox comments are brief articles on stocks in which I am involved. These can come from… Antares: Teva Offer to Buy Mylan Should Have No Effect on Launch of AB Rated Generic to EpiPen (ATRS, $2.76, Buy)Overview Subsequent to my posting of my recent update on Antares, I have seen that Teva has made an offer to… Antares: Detailed Sales and Earnings Projections for 2015 and 2016 (ATRS, Buy, $2.77, subscription required)Investment Thesis Antares Pharmaceuticals: Highlights of Presentation at JP Morgan Conference (ATRS, $2.36. Buy)Investment Overview Antares has hit a somewhat dis-settling stretch as Otrexup prescriptions have recently flattened and the FDA recommended that additional… Delay in Quick Shot Testosterone Clinical Program is Not a Major Setback for the Stock (ATRS, Buy, $2.53)Antares sent out a press release today about a new development in the Quick Shot Testosterone phase 3 program. The Company… Antares: Responding to Two Questions on Teva’s AB Rated Competitor to EpiPen (ATRS, Buy, $2.44)Purpose of the Blog I very much appreciate questions and feedback from subscribers to my website. I have had two recent… Antares: 2015 Could Be the Breakout Year for the Stock (ATRS, $2.24, Buy)
I project 2015 sales of Otrexup at $22 million; if so, it would be generating profit in the latter half… Antares: Although it is Still Early, I Think That Otrexup Launch is Going Very Well (ATRS, Buy, $2.93, Paid subscribers)Investment Thesis The broad based business model of Antares results in its receiving revenues from numerous products that are marketed by… Thoughts on the Market Correction in Biotechnology StocksThis Has Been a Tough Correction The recent sharp market correction and rotation out of growth stocks like biotechnology and technology… Antares (ATRS, Buy, $4.00) Why I Think That the Otrexup Launch Will Be A Success (Paid Subscribers Only)Recent Price Behavior Antares’ (ATRS) price has drifted down since the approval of Otrexup for the treatment of rheumatoid arthritis and… San Francisco Trip Is the Basis for a Preview of 2014 (Subscribers Only)What SmithOnStocks Is All About Antares Marketing Agreement on Otrexup with Leo is a Nice Positive (ATRS, $3.93)Antares is preparing to launch Otrexup for rheumatoid arthritis in the US in late January of 2014 with its own… Antares: Thoughts on the Upcoming Otrexup Launch (ATRS, $3.64)Investment Thesis Antares: An In-Depth Look at Otrexup and Re-iteration of My Buy Recommendation (ATRS: $4.45) (Paid Subscribers Only)Investment Overview and Thesis SmithOnStocks Opines on Stocks May 19, EditionOne Approach for Investing in Emerging Biotechnology Stocks Antares: Reiteration of My Buy Recommendation (ATRS, $4.00)Investment Thesis Antares' Pipeline is Bursting with New Products; Vibex MTX is the Star (ATRS)Investment Opinion Antares: Settlement of Litigation on EpiPen is a Positive (AIS, $3.08)Conclusion Vibex MTX is the Most Exciting Component of the Antares Investment Outlook (AIS, $2.74)Investment Thesis The Promise of the Antares Pipeline is the Basis of my Buy Recommendation (AIS, $2.40)Investment Opinion Antares Is Initated As A Buy Based On Broad, Promising Pipeline (AIS, $2.59)Investment Opinion Libi-Gel Phase III Trial Results Should Be Released Shortly (AIS, $2.73)Investment Overview Collaboration with Teva on Self-Injected Drugs Is the Major Driver of the Investment Thesis (AIS, $2.68)Investment Thesis Approval of Anturol Is Significant Positive (AIS, $2.68)Anturol Approval is A Major Positive Recently, I wrote a note about Anturol discussing its therapeutic profile and the commercialization agreement… Anturol's December 8th PDUFA Date Is Looming (AIS, $2.77)Introduction Antares Initiated As A Buy (AIS, $2.59)Investment Opinion |